Edition:
United States

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

26.05CHF
10:36am EST
Change (% chg)

CHF-0.35 (-1.33%)
Prev Close
CHF26.40
Open
CHF26.95
Day's High
CHF27.50
Day's Low
CHF26.00
Volume
73,034
Avg. Vol
62,189
52-wk High
CHF82.00
52-wk Low
CHF25.10

Summary

Name Age Since Current Position

Elmar Schnee

57 Chairman of the Board

Thomas Meier

55 2017 Chief Executive Officer, Member of the Executive Management Board, Delegate of the Board

Martin Gertsch

52 2017 Vice Chairman of the Board

Christoph Rentsch

58 2015 Chief Financial Officer, Member of the Executive Management Board

Oliver Strub

54 2015 Senior Vice President, General Counsel, Secretary to the Board, Member of the Executive Management Board

Guenther Metz

59 2015 Senior Vice President Business Development, Member of the Executive Management Board

Todd Bazemore

47 2016 Chief Operating Officer Santhera U.S., Member of the Executive Management Board

Kristina Sjoblom Nygren

56 2017 Chief Medical Officer and Head of Development, Member of the Executive Management Board

Giovanni Stropoli

57 2015 Chief Commercial Officer Europe & Rest of World, Member of the Executive Management Board

Philipp Gutzwiller

2017 Director

Patrick Vink

54 2017 Director

Biographies

Name Description

Elmar Schnee

Mr. Elmar J. Schnee serves as Chairman of the Board of Santhera Pharmaceuticals Holding Ltd. He is Member of the Compensation Committee at the Company. He is Advisor to Management of MindMaze, a neuro-technology company spun off from the Swiss Federal Institute of Technology in Lausanne (EPFL). Prior to that, he was Chairman, Chief Executive Officer and Board Member of Cardiorentis in Zug, Switzerland. Previously, he was a General Partner and Member of the Executive Board of Merck KGaA, responsible for its worldwide pharmaceutical business. He also led the major restructuring of the business including the acquisition and integration of Serono. Prior to Merck, Mr. Schnee held senior roles in marketing, licensing, strategy, business development, and as Managing Director with UCB Pharma, Sanofi-Synthelabo, Migliara Kaplan and Fisons. He currently serves on the Board of Directors of listed Jazz Pharmaceuticals and Stallergenes Greer as well as several privately held life science companies.

Thomas Meier

Dr. Thomas Meier, Ph.D., has been Chief Executive Officer, Member of the Executive Management Board andDelegate of the Board of Santhera Pharmaceuticals Holding Ltd since April 4, 2017. He was Chief Executive Officer, Member of the Executive Management Board at Santhera Pharmaceuticals Holding AG since October 1, 2011. Prior to that, he served as Member of the Management Board and Chief Scientific Officer at the Company from 2004. He was founder and former Chief Executive Officer of MyoContract prior to the combination with Graffinity that led to the Company. In 1999, he became Independent Research Group Leader and Lecturer in the Department of Pharmacology and Neurobiology at the Biozentrum of the Universitaet Basel, where he established MyoContract. He received his Doctorate in Philosophy degree in Biology from Universitaet Basel, in 1992, and subsequently joined the University of Colorado Health Sciences Center. He is author of several papers in the field of neuromuscular research. He won the International Research Fellowship Award from the United States National Institutes of Health and has received a long-term fellowship from the Human Frontier Science Foundation. In 2007, he received the BioValley Basel Award for his contributions to the life sciences in the area.

Martin Gertsch

Mr. Martin Gertsch has been Vice Chairman of the Board at Santhera Pharmaceuticals Holding Ltd since 2017. He was Non-Executive Chairman of the Board of Directors of the Company from May 13, 2013. He was Non-Executive Vice Chairman of the Board of Directors at Santhera Pharmaceuticals Holding AG from 2011 till May 13, 2013. Prior to that, he served as Member of the Board of Directors at Santhera Pharmaceuticals Holding AG from 2006. In addition, he has served as Chairman of the Audit Committee at the Company. Up to January 2014, he served as Chief Financial Officer of Acino Holding. Prior to this he was Vice President Head of Finance EMEA at Synthes and held Chief Financial Officer and Chief Operating Officer positions at Delenex Therapeutics and ESBATech, two privately held biotech companies. From 2002 to the beginning of 2006, he was Chief Financial Officer of Straumann, which he had joined in 1997 as Head of Group Controlling and Reporting. Between 1986 and 1997, he was an Audit Engagement Manager at PricewaterhouseCoopers, Basel, Switzerland. He is a Swiss-certified fiduciary and Swiss-certified public accountant. He has also completed several executive-level development programs at IMD (the lnternational Institute for Management Development) in Lausanne, Switzerland. He serves as a Board Member of Evolva Holding, and the University Center of Dentistry, Basel (UZB). He is also Chairman of two diagnostic start-up companies.

Christoph Rentsch

Mr. Christoph Rentsch has served as Chief Financial Officer, Member of the Executive Management Board of Santhera Pharmaceuticals Holding Ltd since July 1, 2015. He started his career in investment banking at Credit Suisse. Subsequently, he worked for Lonza both in Switzerland and the United States. Thereafter he joined Roche as Head of Group Funding and Capital Markets for several years before he became partner of Caperis Ltd, an investment advisory and management firm. Since 2010 he served as Chief Financial Officer of privately-held Polyphor. He holds a degree in economics and business administration from Fachhochschule Basel.

Oliver Strub

Mr. Oliver Strub has been Senior Vice President, General Counsel, Secretary to the Board, Member of the Executive Management Board of Santhera Pharmaceuticals Holding Ltd since February 1, 2015. He is an experienced commercial lawyer, also responsible for the Company’s general legal affairs, insurances, trademarks, human resources and IT. Mr. Strub joined Santhera in 2006 as General Counsel, shortly before the Company listed its shares on the SIX. From 1995 to 2006, he was with Ciba- Geigy, then Ciba Specialty Chemicals (now part of BASF), both Basel, Switzerland, where he was Head Corporate Law and Chief Compliance Officer. He holds a degree in law from Universitaet Basel.

Guenther Metz

Dr. Guenther Metz has been Senior Vice President Business Development, Member of the Executive Management Board of Santhera Pharmaceuticals Holding Ltd since February 1, 2015. He spent more than 20 years in the life science industry and has been working for Santhera since its inception in 2004. He began his career in drug discovery at the French company Fournier Pharma, and thereafter joined the German start-up Graffinity, which in 2004 merged with MyoContract to form Santhera. Dr. Metz held various research management positions in cross functional teams and while working at Santhera gained experience across the preclinical and clinical pharmaceutical value chain in diverse indications. In 2008, he transitioned to a new area of responsibilities in business development and licensing, taking up the role of Vice President (VP) Business Development at Santhera. In 2011, he was appointed VP Operations and Alliance Management. Dr. Metz received his Ph.D. in biophysics from Universitaet Freiburg, Germany, in 1992 and subsequently held a postdoctoral research position at Yale University, New Haven, Connecticut, supported by a fellowship from the Alexander von Humboldt Foundation.

Todd Bazemore

Mr. Todd M. Bazemore has been Chief Operating Officer Santhera U.S., Member of the Executive Management Board at Santhera Pharmaceuticals Holding Ltd since September 6, 2016. Mr. Bazemore is a biopharmaceutical executive with 22 years of experience across multiple therapeutic areas spanning from ultra-rare diseases to large primary care conditions. He has experience launching and building brands and has been instrumental in the success of a number of drugs. Prior to joining Santhera Mr. Bazemore served as EVP and Chief Commercial Officer at Dyax Corp. where he was responsible for global commercial strategy and oversight of all commercial functions. Dyax was acquired by Shire plc in January of 2016. Prior to joining Dyax Mr. Bazemore was at Sunovion Pharmaceuticals (previously Sepracor INC, prior to acquisition by Sumitomo Dainippon Pharma Co., Ltd) where he served in several roles of increasing responsibility including Vice President of Sales, Vice President of Respiratory Business Unit and Vice President of Market Access and Reimbursement. He began his career in sales at MURO Pharmaceuticals. Mr. Bazemore has a Bachelor’s of Science in Health from the University of Massachusetts at Lowell.

Kristina Sjoblom Nygren

Ms. Kristina Sjoblom Nygren, M.D., has been Chief Medical Officer and Head of Development, Member of the Executive Management Board at Santhera Pharmaceuticals Holding Ltd since January 1, 2017. She studied chemistry and biochemistry and graduated as a medical doctor from the Karolinska Institute, Sweden. She brings over 18 years of experience as biopharmaceutical executive in drug development across multiple therapeutic areas, including orphan diseases. During her career she has worked in clinical development roles at Wyeth, AstraZeneca and Biovitrum. Prior to joining Santhera she served as Vice President and Head of Clinical Development at Sobi where she was leading the clinical development of all programs from first in man to commercialization and life cycle management.

Giovanni Stropoli

Mr. Giovanni Stropoli has served as Chief Commercial Officer Europe & Rest of World, Member of the Executive Management Board of Santhera Pharmaceuticals Holding Ltd since February 1, 2015. He is a commercial manager in the pharmaceutical industry. Until January 2015, he served as Senior Vice President for the region called mid-sized countries at InterMune, Switzerland, an orphan drug company acquired by Roche in 2014. For InterMune, Mr. Stropoli launched Esbriet in 11 countries. Before this assignment he was holding several roles at Eisai, Tokyo, Japan, including country manager in Italy, regional manager for Mid-Sized Countries and finally Senior Vice President, New Markets, in London from 2005 until 2011. Before joining Eisai, Mr. Stropoli was country manager Italy for ALK-Abello, Copenhagen. Earlier he held several positions in marketing and sales at Eli Lilly, Indianapolis with assignments in Italy, the United States and Spain. Mr. Stropoli started his professional career in 1998 as sales representative in Alfa-Wassermann, Bologna, Italy. He holds a degree in veterinary medicine from Universita degli Studi di Sassari .

Philipp Gutzwiller

Mr. Philipp Gutzwiller has been Director of Santhera Pharmaceuticals Holding Ltd since April 4, 2017. He is Member of the Audit Committee at the Company. He is Global Head Healthcare at Lloyds Banking Group plc in London. He has accumulated over 15 years of experience as a banker to the broader healthcare industry advising corporate and private equity clients on the assessment, financing and execution of acquisitions and capital market transactions. He started his career at Roche as a finance controller and later worked as an executive in Roche's corporate mergers and acquisitions team.

Patrick Vink

Dr. Patrick Volkert Jozef Johannes Vink, M.D., has been Director of Santhera Pharmaceuticals Holding Ltd since April 4, 2017. He is Chairman of the Compensation Committee at the Company. He has been an advisor to Santhera's Board since 2016. He has over 25 years of life science industry experience. In his latest assignment, he was employed as Chief Operating Officer at Cubist Pharmaceuticals overseeing all worldwide commercial and technical operations as well as global alliance management. Previously, he held several senior management positions with Mylan Inc., Novartis Generics/Sandoz, Biogen and Sanofi Synthelabo. He serves as Chairman of privately held NMD Pharma and Acacia Pharma and is Member of the Board of Directors of listed Concordia International Corp. and several privately held life science companies.